Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK129 in Advanced Malignant Tumors
NCT05645276Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2023
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK129 in cancer, sponsored by Akeso, Inc. Primary endpoints: Adverse Events, Serious Adverse Events and 4 more. Started Mar 2023; status: completed.
02
Drugs
AK129
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05645276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645276.